A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | MicrobiomeTrials← Back to trialsNCT07491172
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-06-21Est. Completion: 2027-06
Enrollment target: 90 participants Locations- Integrity Clinical Research, Hialeah, Florida, United States
- Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
- Flourish Orlando, Orlando, Florida, United States
- United Medical Research, Port Orange, Florida, United States
- University of Rochester, Rochester, New York, United States
- Duke Early Phase Clinical Research, Durham, North Carolina, United States
- Peters Medical Research, High Point, North Carolina, United States
- Oregon Health & Science University (OHSU), Portland, Oregon, United States
- Royal Adelaide, Adelaide, Australia
- CORE Research, Brisbane, Australia
- Royal Prince Alfred Hospital, Camperdown, Australia
- Austin Health, Heidelberg, Australia
- Monash Medical Center, Melbourne, Australia
- Aotearoa, Auckland, New Zealand
- NZCR, Christchurch, New Zealand
- Royal Papworth Hospital, Cambridge, United Kingdom
- Richmond Pharmacology, London, United Kingdom
Other microbiome trials you might be interested in
Atrial Fibrillation (AF)
The goal of this clinical trial is to learn if the cardiac pulsed field ablation system, composed of the cardiac pulsed …
Multiple LocationsEst. completion Mar 2028
Type 2 Diabetes Mellitus (T2DM)
This randomized controlled trial will evaluate the effect of digital-supported foot care education on foot care knowledg…
Siirt, Turkey (Türkiye)Est. completion Jul 15, 2027
Arteriosclerosis Obliterans
This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome …
Guangzhou, ChinaEst. completion Jul 2027